利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.018 秒)

    Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
    1.
    发明授权
    Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof 有权

    公开(公告)号：US11942149B2

    公开(公告)日：2024-03-26

    申请号：US17883158

    申请日：2022-08-08

    申请人： MacroGenics, Inc.

    发明人： Liqin Liu ,  Chia-Ying Kao Lam ,  Gundo Diedrich ,  Leslie S. Johnson ,  Paul A. Moore ,  Ezio Bonvini

    IPC分类号： G11C13/00 ,  G11C15/00

    CPC分类号： G11C13/0026 ,  G11C13/004 ,  G11C15/00 ,  G11C2013/0045

    摘要： The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA. The CD137×TA Binding Molecules of the invention are capable of simultaneous binding to CD137, and a TA. The invention is directed to pharmaceutical compositions that contain any such CD137×TA Binding Molecules. The invention is additionally directed to methods for the use of such molecules in the treatment of cancer and other diseases and conditions. The invention also provides novel CD137-binding molecules, and HER2/neu-binding molecules, as well as derivatives thereof and uses thereof.

    Bispecific CD16-Binding Molecules and Their Use in the Treatment of Disease
    4.
    发明申请
    Bispecific CD16-Binding Molecules and Their Use in the Treatment of Disease 有权

    公开(公告)号：US20210171630A1

    公开(公告)日：2021-06-10

    申请号：US16771377

    申请日：2018-12-06

    申请人： MacroGenics, Inc.

    发明人： Gundo Diedrich ,  Liqin Liu ,  Hua Watson Li ,  Leslie S. Johnson

    IPC分类号： C07K16/28 ,  C07K16/32 ,  C07K16/10 ,  A61P31/18 ,  A61P35/00

    摘要： The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a “CD16 Binding Molecule”). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen (“DA”) (e.g., a “CD16 x DA Binding Molecule”). The present invention is particularly directed to such CD16 x DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16 x DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16. The invention particularly concerns the use of such CD16 and CD16 x DA Binding Molecules in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s).

    Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
    7.
    发明授权
    Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof 有权

    公开(公告)号：US11459394B2

    公开(公告)日：2022-10-04

    申请号：US16488025

    申请日：2018-02-22

    申请人： MacroGenics, Inc.

    发明人： Liqin Liu ,  Chia-Ying Kao Lam ,  Gundo Diedrich ,  Leslie S. Johnson ,  Paul A. Moore ,  Ezio Bonvini

    IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  C07K16/32 ,  A61K39/00

    摘要： The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA. The CD137×TA Binding Molecules of the invention are capable of simultaneous binding to CD137, and a TA. The invention is directed to pharmaceutical compositions that contain any such CD137×TA Binding Molecules. The invention is additionally directed to methods for the use of such molecules in the treatment of cancer and other diseases and conditions. The invention also provides novel CD137-binding molecules, and HER2/neu-binding molecules, as well as derivatives thereof and uses thereof.

    Optimized gp41-Binding Molecules and Uses Thereof
    9.
    发明申请
    Optimized gp41-Binding Molecules and Uses Thereof 有权

    公开(公告)号：US20210246194A1

    公开(公告)日：2021-08-12

    申请号：US17055805

    申请日：2019-05-13

    申请人： MacroGenics, Inc. ,  Duke University

    发明人： Chia-Ying Kao Lam ,  Gundo Diedrich ,  Jeffrey Lee Nordstrom ,  Liqin Liu ,  Leslie S. Johnson ,  Scott Koenig ,  Barton F. Haynes ,  Guido Ferrari

    IPC分类号： C07K16/10 ,  C07K16/28 ,  A61K39/42 ,  A61K45/06

    摘要： The present invention is directed to optimized HIV-1 gp41-Binding Molecules having reduced immunogenicity. More specifically, the invention relates to optimized gp41-Binding Molecules that comprise a gp41-binding Variable Light Chain (VL) Domain and/or a gp41-binding Variable Heavy Chain (VH) Domain that has/have been optimized to reduce the immunogenicity of such Domain(s) upon administration to a recipient subject. The invention particularly pertains to gp41-Binding Molecules that are multispecific gp41-Binding Molecules (including bispecific diabodies (including DART® diabodies), BiTE®s, bispecific antibodies, trivalent binding molecules (including TRIDENT™ molecules), etc.) that comprise: (i) such optimized gp41-binding Variable Domain(s) and (ii) a domain capable of binding to an epitope of a molecule present on the surface of an effector cell. The invention is also directed to pharmaceutical compositions that comprise any of such gp41-Binding Molecules, and to methods involving the use of any of such gp41-Binding Molecules in the treatment of HIV-1 infection.